07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Gamida Cell, Novartis deal

If Novartis had exercised the option, Gamida would have received $165 million up front and been eligible for up to $435 million in milestones related to the development of Gamida’s NiCord therapy (see BioCentury, Sept....
08:00 , Feb 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Chemokine (CXC motif) ligand 14 (CXCL14; BRAK) In vitro and mouse studies suggest that antagonizing CXCL14 could help...
07:00 , May 15, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Chagas disease Cruzain An SAR study identified a small molecule irreversible inhibitor of cruzain that may be useful for treating...